SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?


To: phoenix_rising who wrote (1257)6/2/2015 3:08:14 AM
From: Mirror Image  Read Replies (2) | Respond to of 2026
 
I see what you are talking about Phoenix. It looks like they actually ran 3 different Phase 2 trials on Fispemifene previously. And the highest dosage was 300 mg. I do not have any first hand experience on trials though. So I can't say that this dosage increase is normal or abnormal. I would assume that they are trying to figure out the best dosage at this point.

clinicaltrials.gov